Extemporaneous Compounding and Physiological Modeling of Amlodipine/Valsartan Suspension

Table 4

The mean percentage of the active ingredient in AML/VAL suspension throughout 4-week period at room temperature.

Weak	% of remaining drug
	AML	VAL
Initial	102.1	106.2
Week 1	101.8	105.3
Week 2	99.1	102.2
Week 3	98.3	101.9
Week 4	97.3	101.1